Ionis Pharmaceuticals, Inc. · 1 day ago
2026 Summer Intern | Formulation & Delivery Sciences
Ionis Pharmaceuticals, Inc. is a pioneer in RNA-targeted medicines, discovering breakthroughs that redefine life for patients with serious diseases. The Summer Intern in Formulation & Delivery Sciences will contribute to the design and formulation of lipid nanoparticles for extrahepatic delivery, gaining valuable biotechnology skills in a dynamic team environment.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Contribute to the design, production, characterization, and testing of LNPs
Assess LNP binding to cells in vitro, and assist with maintenance of cell lines
Assist with in vivo work as needed
Thoroughly document results in electronic lab notebooks and present findings
Analyze experimental data and present scientific results
Qualification
Required
MUST be currently enrolled in a U.S. Undergraduate and/or Graduate Degree Program and not graduating prior to the completion of the Ionis internship
MUST be able to begin internship between 6/8 and 8/14/2026
MUST be able and willing to remain in program through at least 8/14/2026
MUST be able and willing to commit to a minimum 40-hour work week
Preferred
Experience formulating and characterizing lipid nanoparticles and/or experience with cell culture and in vivo work is a plus
Benefits
Weekly stipend (for onsite interns only)
Housing/Travel assistance available for eligible, out-of-area interns
Networking and bonding social events
Company
Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases.
H1B Sponsorship
Ionis Pharmaceuticals, Inc. has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (8)
2024 (5)
2023 (3)
2022 (5)
2021 (5)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$2.45B2025-11-13Post Ipo Debt· $700M
2024-09-09Post Ipo Equity· $500.3M
2023-06-06Post Ipo Debt· $500M
Leadership Team
Recent News
Labiotech UG
2026-01-22
Business Wire
2026-01-22
Company data provided by crunchbase